Moderna Stock No-Brainer After FDA Win: Buy or Not?
A recent FDA decision sparked a powerful rally in Moderna shares, but is the move enough to call it a no-brainer? Thi...
A practical intro to yield programs for USDC, focusing on how to earn with confidence and manage associated risks. Learn the basics and start optimizing today.
12,846 articlesA recent FDA decision sparked a powerful rally in Moderna shares, but is the move enough to call it a no-brainer? Thi...
Two separate California cases show how funds meant for students can be diverted into luxury purchases. This article e...
When a biotech deal moves a small cap, it can set the tone for the whole sector. This story explains what happened wi...
In 2026, some markets will heat up while others cool down. This guide outlines the 10 markets where prices will rise ...
Grail stock faced another sharp move as trial news weighed on sentiment. This guide unpacks why the slump happened, w...
The 30-year fixed mortgage rate falls below 6% for the first time since 2022, shaking up affordability for buyers as ...
As Verastem prepares for its 2025 earnings outlook, investors should focus on cash runway, collaboration milestones, ...
A missing, nationwide accounting of subsidies per affordable unit clouds the price tag of affordable housing. This re...
Two early leaders in the electric air taxi race collide with a policy signal that could tilt the field. This analysis...
A 40-year-old Democrat who owns a fitness company focused on pregnant and postpartum women pulled off a tight victory...
A fresh set of loan programs is rolling out as mortgage rates stay high and prices stay elevated, aiming to ease the ...
Space stocks offer a compelling diversification away from AI hype. This guide explains why more these space stocks ma...